OR WAIT null SECS
July 03, 2021
Particle performance in a DPI can be optimized by fine-tuning the formulation and manufacturing process parameters.
July 01, 2021
Vectura will provide preclinical development services for Incannex’s inhaled drug product for the treatment of traumatic brain injury.
June 22, 2021
Vectura has signed an agreement with Incannex Healthcare for the pre-clinical development of IHL-216A, an inhaled drug product for the treatment of traumatic brain injury.
May 07, 2021
Vectura and Inspira Pharmaceuticals have joined forces to develop a potential inhaled therapy for COVID-19.
March 10, 2021
The expansion plans to increase Vectura’s DPI dosage form development, specifically its unit dose and multi-dose inhalers, and integrated device design and manufacturing for customer programs.
December 08, 2020
A development agreement will study inhaled formulations of cannabinoid-based drug product for central nervous system diseases.
September 14, 2020
Vectura will support the product from Phase I through to commercial launch.
September 02, 2020
Creating an inhaled formulation is one way in which improved efficacy or added value can be achieved in projects to repurpose or reposition existing drugs.
September 01, 2020
The Ventofor Combi Fix will be brought into the Turkish market via Bilim’s development program, while the PowdAir Plus DPI is manufactured and commercialized by H&T Presspart under a patent license from Hovione.
February 12, 2020
Inhalation drug delivery company Vectura announces new organizational structure to drive innovation, customer focus, and growth.